MAHWAH, N.J. / Nov 02, 2023 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in two upcoming investor conferences.
KORU Medical's management is participating at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16th, 2023.
KORU Medical's management will also be participating at the 14th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16th, 2023.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
| Last Trade: | US$5.91 |
| Daily Change: | 0.11 1.90 |
| Daily Volume: | 153,544 |
| Market Cap: | US$273.750M |
November 12, 2025 November 04, 2025 September 18, 2025 August 06, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
